source
- Pharma deals in China face heightened IP risk under U.S. BIOSECURE ActPharma companies are increasing licensing activity in China, but experts say patent attorneys must now factor in the geopolitical implications of the BIOSECURE Act. The legislation seeks to compil…
- GSK launches $2.5 billion restructuring plan to fund late-stage pipeline and offset upcoming HIV drug patent lossGSK reported $2.4 billion in impairment charges for the second quarter and unveiled a three‑year restructuring designed to save roughly $2.5 billion. The company says the savings will be redirecte…